Literature DB >> 25824678

Therapy: Lenvatinib and radioiodine-refractory thyroid cancers.

Lara Dunn1, James A Fagin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25824678      PMCID： PMC4518863          DOI： 10.1038/nrendo.2015.53

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  8 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

Review 2.  Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.

Authors:  Rakesh K Jain
Journal:  Cancer Cell       Date:  2014-11-10       Impact factor: 31.743

3.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

Review 4.  Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets.

Authors:  Jeffrey A Knauf; James A Fagin
Journal:  Curr Opin Cell Biol       Date:  2009-02-21       Impact factor: 8.382

5.  Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

Authors:  Junji Matsui; Yasuhiro Funahashi; Toshimitsu Uenaka; Tatsuo Watanabe; Akihiko Tsuruoka; Makoto Asada
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

6.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.

Authors:  Junji Matsui; Yuji Yamamoto; Yasuhiro Funahashi; Akihiko Tsuruoka; Tatsuo Watanabe; Toshiaki Wakabayashi; Toshimitsu Uenaka; Makoto Asada
Journal:  Int J Cancer       Date:  2008-02-01       Impact factor: 7.396

Review 7.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.

Authors:  Rakesh K Jain
Journal:  J Clin Oncol       Date:  2013-05-13       Impact factor: 44.544

8.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
  8 in total
  6 in total

1.  Peptide P11 suppresses the growth of human thyroid carcinoma by inhibiting the PI3K/AKT/mTOR signaling pathway.

Authors:  Dongdong Wu; Wenke Tian; Jianmei Li; Qianqian Zhang; Honggang Wang; Lei Zhang; Zhongwen Xie; Ailing Ji; Yanzhang Li
Journal:  Mol Biol Rep       Date:  2019-04-26       Impact factor: 2.316

Review 2.  Biologic and Clinical Perspectives on Thyroid Cancer.

Authors:  James A Fagin; Samuel A Wells
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

3.  Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.

Authors:  Katie M Mishall; Thomas C Beadnell; Brent M Kuenzi; Dorothy M Klimczak; Giulio Superti-Furga; Uwe Rix; Rebecca E Schweppe
Journal:  Oncotarget       Date:  2017-08-24

4.  Long-term efficacy and safety of fourth-line multikinase inhibitor treatment with lenvatinib in a young papillary thyroid carcinoma patient.

Authors:  S Morelli; E Puxeddu
Journal:  Drugs Context       Date:  2017-07-26

Review 5.  Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications.

Authors:  Sagit Zolotov
Journal:  Rambam Maimonides Med J       Date:  2016-01-28

Review 6.  Therapeutic advances in anaplastic thyroid cancer: a current perspective.

Authors:  Shikha Saini; Kiara Tulla; Ajay V Maker; Kenneth D Burman; Bellur S Prabhakar
Journal:  Mol Cancer       Date:  2018-10-23       Impact factor: 27.401
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.